AC

Arthur Child Comprehensive Cancer Centre at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Arthur Child Comprehensive Cancer Centre takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on advanced kidney cancer and treatment choices along the patient journey. It presents the final analysis of a phase 3 trial of belzutifan plus lenvatinib against cabozantinib after PD-1 or PD-L1 immunotherapy, and how quality of life relates to efficacy in that trial.

Organization

ESMO 2026 Attendance

AC

Arthur Child Comprehensive Cancer Centre

Calgary, Canada

Cancer centre & hospital

Comprehensive cancer centre in Calgary, Alberta, Canada, part of the province's public cancer care system.

Satellite

Sat Oct 24
18:43–19:23

Navigating the RCC treatment journey

Ipsen - Treatment decisions that shape the journey in RCC and NETs · with Gustave Roussy, City of Hope

Genitourinary cancersSarcoma, CNS, head & neck and rare cancers

Abstract

Sun Oct 25
08:40–08:50

3587O - Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy

Proffered paper 2: Genitourinary tumours, renal and urothelial

Genitourinary cancers

Abstract

Sun Oct 25
15:49–15:54

3595RO - Relationship between health-related quality of life (HRQoL) and efficacy in LITESPARK-011: Belzutifan (belz) + lenvatinib (len) versus cabozantinib (cabo) in advanced clear cell renal cell carcinoma (ccRCC) after anti–PD-(L)1 therapy

Rapid oral 2: Genitourinary tumours, renal and urothelial

Genitourinary cancers

Instantly find 20 buyers from Arthur Child Comprehensive Cancer Centre

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction